A Californian start-up will be allowed to advertise a mail order DNA test that screens for a rare genetic condition, after a U-turn by the US regulator.
The Food and Drug Administration (FDA), said the 23andMe product would "provide people with information about possible mutations in their genes that could be passed on to their children".
It had previously banned similar tests.
The 23andMe kit screens for Bloom syndrome, an inherited disease that is most common among Ashkenazi Jews.
It can detect whether a healthy person is a carrier of the genetic variant that causes the disorder, and therefore at risk of passing it on to their offspring.
'No test is perfect'
In a statement, the FDA also said it would provide the "least burdensome regulatory path" for future projects from 23andMe and similar companies.
"In many circumstances it is not necessary for consumers to go through a licensed practitioner to have direct access to their personal genetic information," the regulator added.
The decision contrasts with the FDA's stance in 2013, when it ordered 23andMe to "immediately discontinue" selling its saliva collection tests after failing to provide information to back its marketing claims.
The $99 test had offered users a readout of their genetic code, including a detailed analysis of their health risks.
However, despite giving the Bloom syndrome kit a green light, the FDA cautioned that "no test is perfect" and suggested that the kit should only be used by those likely to carry a relevant gene.
Informative labelling and information on how to follow up with a medical professional must be provided by 23andMe, the FDA said.
'Major milestone'
While welcoming the FDA's decision, 23andMe said it would "not return health results on individually cleared reports" until it had a "comprehensive product offering" in place.
The health tech company, which is backed by Google, has been operating since 2006 and was co-founded by Anne Wojcicki, its chief executive, who married Google co-founder Sergey Brin in 2007.
"This is a major milestone for our company and for consumers who want direct access to genetic testing," she said in a blog post.
"We have more work to do, but we remain committed to pursuing a regulatory path for additional tests and bringing the health reports back to the US market."
Latest Stories
-
Koda should have visited the pastor to avert the prophecy – Ajagurajah
20 mins -
Emotional support alligator taken and released in swamp
27 mins -
A mate is a mate, Bawumia can’t be in the driver’s seat – NDC Communicator
29 mins -
Over 400 million Google accounts have used passkeys, but our passwordless future remains elusive
32 mins -
Kwame Nkrumah Memorial Park surpasses Aburi Gardens as most visited site in 2023 – GTA
34 mins -
Third IFC EDGE Students Design Competition opens in Ghana
43 mins -
Baidoo: Disgraceful maltreatment of the Black Princesses must stop
52 mins -
Telecel Ghana commits to community collaboration during Western Region tour
1 hour -
Chieftaincy Ministry shouldn’t have written the letter – Atuguba on Akufo-Addo-chiefs saga
1 hour -
Joe Vibe strikes a ‘Pose’ with new song
1 hour -
Works begin on inner-city roads in Ho
1 hour -
GJA to commemorate World Press Freedom Day in Koforidua
2 hours -
West Ham ban director Tim Steidten from dressing room as search continues for new manager
2 hours -
I haven’t been treated well by the NPP but I remain loyal – Former NPP MP
2 hours -
IGP petitioned to probe Kwadaso MP over ‘white envelope’ incident
2 hours